A Randomized, Open Labelled Trial of Continuation of Adefovir Plus Lamivudine Versus Switching to Adefovir Plus Entecavir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Adefovir Plus Lamivudine.

Trial Profile

A Randomized, Open Labelled Trial of Continuation of Adefovir Plus Lamivudine Versus Switching to Adefovir Plus Entecavir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Adefovir Plus Lamivudine.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2014

At a glance

  • Drugs Entecavir (Primary) ; Adefovir; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms CAESAR
  • Sponsors Asan Medical Center
  • Most Recent Events

    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Dec 2010 The treatment duration changed from 52 weeks to 104 weeks according to ClinicalTrials.gov record.
    • 02 Dec 2010 Planned End Date changed from 1 Dec 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top